Medical Cannabis for Crohn's Disease & IBD — UK Patient Guide

IBD and the Search for Better Symptom Management

Inflammatory bowel disease (IBD) — including Crohn's disease and ulcerative colitis — affects over 500,000 people in the UK. While conventional treatments including biologics, immunosuppressants and surgery have transformed outcomes for many patients, a significant proportion continue to experience chronic pain, cramping, nausea, urgency and fatigue that impairs quality of life. It is in this context that medical cannabis has attracted growing interest.

How Cannabis Interacts With the Gut

The gastrointestinal tract is densely packed with endocannabinoid system (ECS) receptors, particularly CB1 and CB2 receptors. The ECS plays a role in regulating intestinal motility, secretion, visceral pain and immune cell activity — all of which are disrupted in IBD. This biological rationale has driven research into whether cannabinoids can modulate the inflammatory and symptomatic aspects of IBD.

What the Evidence Shows

The evidence base for cannabis in IBD is growing but remains at an early stage for definitive clinical recommendations.

Crohn's Disease

• A landmark Israeli trial found that inhaled cannabis reduced Crohn's Disease Activity Index (CDAI) scores significantly compared to placebo, with complete remission in five of eleven cannabis-treated patients.
• Subsequent studies have demonstrated subjective improvements in pain, sleep, appetite and general wellbeing in Crohn's patients using cannabis.
• Evidence that cannabis achieves mucosal healing or reduces inflammatory markers (CRP, calprotectin) is more limited — symptom improvement may occur independently of underlying inflammation control.

Ulcerative Colitis

• A UK trial testing CBD capsules in UC patients did not demonstrate significant improvement in remission rates over placebo, though quality of life scores improved subjectively.
• Patient registry data consistently shows high rates of self-reported symptom relief for pain, nausea and urgency.

Symptoms Cannabis May Help Manage

• Abdominal pain: One of the most consistently reported benefits in IBD patient surveys.
• Nausea and appetite loss: THC has well-established antiemetic properties recognised in UK licensing for chemotherapy contexts.
• Sleep disruption: A common secondary burden of IBD — cannabis may help break the cycle of pain-disrupted sleep.
• Anxiety and psychological burden: IBD carries significant mental health comorbidity; CBD-dominant products may provide benefit here.

Getting a Prescription for IBD in the UK

IBD is not a listed indication for NHS medical cannabis prescribing. However, UK private cannabis clinics can prescribe for the symptomatic management of conditions including chronic pain associated with IBD, nausea, and anxiety. Your specialist will assess whether your current conventional treatment regimen has been optimised before considering cannabis as an adjunct.

Find a clinic experienced in gastrointestinal conditions by browsing our UK cannabis clinic directory. Telehealth consultations mean you can access specialist care regardless of your location.

Important Considerations for IBD Patients

Smoking vs Vaporising

Smoking cannabis is harmful and not recommended. Medical vaporisers heat flower to release cannabinoids without combustion — a much safer delivery method. However, for patients with severe flares or those who prefer not to inhale, oils remain a viable option.

Drug Interactions

Cannabis — particularly CBD — can interact with medications commonly used in IBD, including:

• Azathioprine and other immunosuppressants.
• Methotrexate — CBD may affect liver enzyme levels.
• Biologics such as adalimumab — interactions are not well studied; monitoring is advised.

Always provide your prescribing specialist with a full and current medication list before starting any cannabis product.

What to Expect From a Cannabis Prescription for IBD

A typical starting point is a low-dose CBD-dominant oil taken twice daily, with dose increases at monthly review appointments. If pain is the primary concern, a low-dose THC product may be added, often as a night-time dose. Patient response varies: some individuals report dramatic improvement within weeks, while others notice only modest benefit after several months. See our titration guide for more on managing dose adjustments.

Explore currently available medical cannabis products to understand the oil and flower options accessible in the UK.

Key Takeaways

• Evidence supports symptomatic benefit (pain, nausea, sleep) rather than remission induction in IBD.
• UK private clinics can prescribe cannabis for IBD-associated chronic pain, nausea and sleep disturbance.
• Drug interactions with IBD medications are a serious consideration — full medication disclosure is essential.
• Start with low-dose CBD and titrate slowly under specialist supervision.
• Cannabis is an adjunct to, not a replacement for, conventional IBD therapy.